Inter-assay discordance between STRATIFY and IMMUNOWELL is largely threshold-driven and substantially attenuated when applying clinically meaningful PML risk categories. These findings support practical interchangeability for routine monitoring in the biosimilar era, while underscoring the need for cautious interpretation of borderline results.
Chisari et al. (Fri,) studied this question.